In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Humacyte Inc’s stock clocked out at $1.54, up 3.36% from its previous closing price of $1.49. In other words, the price has increased by $3.36 from its previous closing price. On the day, 1.81 million shares were traded. HUMA stock price reached its highest trading level at $1.54 during the session, while it also had its lowest trading level at $1.44.
Ratios:
To gain a deeper understanding of HUMA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, Reiterated its Buy rating but revised its target price to $15 from $12 previously.
On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.
Piper Sandler Upgraded its Underweight to Neutral on August 14, 2023, whereas the target price for the stock was revised from $2.75 to $3.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 14 ’25 when Scheessele William John bought 6,493 shares for $1.54 per share. The transaction valued at 9,999 led to the insider holds 22,018 shares of the business.
Sander Dale A. bought 20,000 shares of HUMA for $30,600 on Apr 10 ’25. The CFO and Chief Corp. Deve. Off. now owns 40,600 shares after completing the transaction at $1.53 per share. On Apr 10 ’25, another insider, Parikh Shamik J, who serves as the Chief Medical Officer of the company, bought 7,500 shares for $1.55 each. As a result, the insider paid 11,625 and bolstered with 7,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 238883264 and an Enterprise Value of 275236992.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.64, which has changed by -0.50641024 over the last 52 weeks, in comparison to a change of 0.07455289 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is -46.60%, while the 200-Day Moving Average is calculated to be -68.71%.
Shares Statistics:
It appears that HUMA traded 3.47M shares on average per day over the past three months and 4537780 shares per day over the past ten days. A total of 130.03M shares are outstanding, with a floating share count of 125.74M. Insiders hold about 18.94% of the company’s shares, while institutions hold 27.77% stake in the company. Shares short for HUMA as of 1743379200 were 27135345 with a Short Ratio of 7.81, compared to 1740700800 on 25475658. Therefore, it implies a Short% of Shares Outstanding of 27135345 and a Short% of Float of 21.48.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
